What is Biodexa Pharmaceticals?
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 982.95K.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.